Second dose of targeted combo shows promise for tough breast cancer
NCT ID NCT02514681
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 22 times
Summary
This study looked at whether giving pertuzumab again, along with trastuzumab and chemotherapy, helps people with advanced HER2-positive breast cancer live longer without their disease getting worse. About 226 adults who had already been treated with pertuzumab took part. The goal was to see if retreatment works better than just trastuzumab and chemo alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aichi Cancer Center
Chikusa-ku, Aichi-ken, 4648681, Japan
-
Japan Breast Cancer Research Group
Chuo-ku, Nihonbashi, Koami-cho, Tokyo, 1030016, Japan
-
Kumamoto University Hospital
Kumamoto, Kumamoto, 8608556, Japan
Conditions
Explore the condition pages connected to this study.